KROS

Keros Therapeutics Inc.

Price

$11.10

return (12m)

-23.40%

p/e

-2.42

p/bv

0.77

DIVIDEND YIELD

0.00%

KROS price

Keros Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KROS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

4.72%

3 months

-1.07%

1 year

-23.40%

2 years

-76.55%

5 years

-65.21%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KROS

Valuation

P/E

-2.42

Sector -4.38

Industry -4.38

P/BV

0.77

Sector 2.02

Industry 2.02

P/Revenue (PSR)

13.42

Sector -4.40

Industry -4.40

EV/EBITDA

1.84

Sector -263.09

Industry -263.09

EV/EBIT

1.82

Sector -702.90

Industry -702.90

P/EBITDA

-2.02

Sector -4.39

Industry -4.39

P/EBIT

-1.98

Sector -4.73

Industry -4.73

P/Total Assets

0.70

Sector 1.49

Industry 1.49

P/Net Current Assets

0.83

Sector -11.70

Industry -11.70

P/Working Capital

0.79

Sector -3.19

Industry -3.19

EPS

-4.16

Sector -2.14

Industry -2.14

BVPS

13.12

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-31.70%

Sector -65.14%

Industry -65.14%

ROA

-28.92%

Sector -65.53%

Industry -65.53%

ROIC

-444.82%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

21.97

Sector 2.90

Industry 2.90

Net Debt / EBITDA

8.44

Sector -6.07

Industry -6.07

Net Debt / EBIT

8.33

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.98

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.91

Sector 0.41

Industry 0.41

Liabilities/Assets

0.09

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-5.67%

Sector -

Industry -

5Y Earnings CAGR

7.20%

Sector -

Industry -

Fundamentals KROS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KROS Keros Therapeutics Inc.	$11.10	-23.55%	0.00%	-2.42	0.77	-31.70%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KROS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Keros Therapeutics

Keros Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2020

Time since IPO - 6 years

23

Employees

Keros Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $201.40 million, with shareholders equity totaling $262.32 million.

The company employs approximately 23 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Keros Therapeutics Inc. reported $15.01 million in revenue, generating net income of $-83.16 million.

Key financial metrics include a P/E ratio of -2.42, a price-to-book (P/B) ratio of 0.77, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KROS.

Market cap

$201.40 million

Net worth

$262.32 million

$262,320,000.00

Assets

$287.60 million

$287,600,000.00

Total Shares Outstanding

20.00 million

20,000,000

Average Daily Trading Volume

$256.81 Thousand

$256,810.34

Sector

Health Care

Industry

Biotechnology

KROS

KROS revenue and profits

Financial Results KROS

DRAG THE FRAME TO SEE MORE DATA

KROS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Keros Therapeutics (KROS) today?

A cotação de Keros Therapeutics (KROS) hoje está em US$ 11.10, com uma variação de -23.4% em relação ao último ano. A cotação de Keros Therapeutics (KROS) iniciou o ano negociando na casa dos US$ 20.36 e hoje está em US$ 11.10. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Keros Therapeutics (KROS) e dados de ações do Ibovespa e mercados internacionais.

Quando Keros Therapeutics (KROS) paga dividendos?

Keros Therapeutics (KROS) não distribuiu dividendos no último ano.

Is Keros Therapeutics (KROS) a good investment?

Atualmente, Keros Therapeutics (KROS) está cotada a US$ 11.10, com um P/L de -2.42, representando um desvio de -489% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -23.4 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -23.40%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Keros Therapeutics (KROS) stock?

Investir em ações de Keros Therapeutics (KROS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Keros Therapeutics (KROS) yield today?

A rentabilidade de Keros Therapeutics (KROS) foi de 4.72% no último mês, -23.40% no último ano e -65.21% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Keros Therapeutics (KROS) hoje, o investimento total seria de US$ 1,110.00, com base na cotação atual de US$ 11.10.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 850.26
Em 5 anos: US$ 386.17
Em 10 anos: US$ 1,110.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KROS

Keros Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KROS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING KROS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Keros Therapeutics

Keros Therapeutics Inc.

United States

11 years

2020

23

PROFIT X PRICE KROS

Financial Results KROS

KROS cash flow

Asset, Revenue and Profit Growth - KROS

KROS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions